STOCKS TELEGRAPH

Author: ST Staff

3 Stocks to Watch Before the Next Rally: Cardiol Therapeutics (CRDL), Minerva Neurosciences (NERV), Coeptis Therapeutics (COEP)

Amid a rapidly evolving financial landscape, investors are casting a wider net in search of high-growth opportunities beyond traditional blue-chip names. Emerging sectors—particularly healthcare, biotechnology, and life sciences—are drawing renewed interest as innovation accelerates and smaller companies demonstrate their ability to disrupt established markets. This shift is prompting closer scrutiny of under-the-radar stocks with strong upside potential.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is facing near-term volatility while continuing to execute on a long-term strategy centered around targeted anti-inflammatory therapies for cardiovascular disease. Despite recent price pressure, the company remains positioned within a high-value segment of biotech where clinical progress, rather than short-term sentiment, is the primary driver of valuation.

Market Momentum

As of April 23, 2026, CRDL closed at $1.36, plunging 9.93%, with trading volume (853,277 shares) above its average of 657,898 shares—indicating elevated selling pressure and active market participation. With a market cap of $151.885M, the stock remains within its 52-week range ($0.8800–$1.71). A 1-year target estimate of $7.44 continues to suggest significant upside potential, implying that recent weakness may reflect short-term sentiment rather than a shift in fundamentals.

Clinical Focus: MAVERIC Trial

The Phase III MAVERIC trial remains the company’s most important catalyst, evaluating CardiolRx™ in recurrent pericarditis. This late-stage study is designed to confirm earlier findings showing reductions in pain and inflammation, with the goal of demonstrating a meaningful impact on disease recurrence. Success in this trial could support a New Drug Application and mark a critical step toward commercialization.

Regulatory & Competitive Positioning

CardiolRx™ has been granted FDA Orphan Drug Designation, offering potential benefits such as market exclusivity and regulatory support. Combined with its non-immunosuppressive approach, the therapy may provide a safer alternative to current treatments, which often rely on steroids or biologics.

Outlook

While recent market weakness highlights volatility, Cardiol’s core investment thesis remains tied to upcoming clinical milestones. Positive Phase III results could serve as a major inflection point and drive a re-rating of the stock.

Minerva Neurosciences Inc (NERV)

Minerva Neurosciences Inc (NASDAQ: NERV) started the day on April 23, 2026, with a price decrease of -7.07% at $6.83. During the day, the stock rose to $7.42 and sunk to $6.83. Taking a more long-term approach, NERV posted a 52-week range of $1.30-$12.46.

Nevertheless, stock’s Earnings Per Share (EPS) this year is 61.73%. This publicly-traded company’s shares outstanding now amounts to $43.27 million, simultaneously with a float of $35.74 million. The organization now has a market capitalization sitting at $295.57 million. It’s Quick Ratio in the last reported quarter now stands at 36.28. In the same vein, NERV’s Diluted EPS trailing twelve months is recorded -26.80, a figure that is expected to reach -0.13 in the next quarter, and analysts are predicting that it will be -0.65 at the market close of one year from today.

Coeptis Therapeutics Holdings Inc (COEP)

As of April 23, 2026, Coeptis Therapeutics Holdings Inc (NASDAQ: COEP) got off with the flyer as it spiked 7.35% to $16.21. During the day, the stock rose to $16.33 and sunk to $15.00. Taking a more long-term approach, COEP posted a 52-week range of $6.26-$21.41.

In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 40.22%. Meanwhile, its Annual Earning per share during the time was 40.22%. This publicly-traded company’s shares outstanding now amounts to $5.75 million, simultaneously with a float of $5.09 million. The organization now has a market capitalization sitting at $100.88 million.

April 24, 2026
3 Stocks That Could Rally Soon: MindWalk (HYFT), Cardiol Therapeutics (CRDL), SOPHiA Genetics SA (SOPH)

Changes in trading behavior frequently act as an early indicator of evolving market dynamics. Over the past few sessions, a cluster of healthcare equities has recorded increased volume, suggesting that more investors are stepping into the space. Such activity often signals a growing curiosity around lesser-known firms that could be gaining momentum.

MindWalk Holdings Corp (HYFT)

MindWalk Holdings Corp (NASDAQ: HYFT) established an initial surge of 4.84% at $1.3, as the Stock market unbolted on April 22, 2026. During the day, the stock rose to $1.33 and sank to $1.26. Taking a more long-term approach, HYFT posted a 52-week range of $0.40-$3.25.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -19.06%. Meanwhile, its Annual Earnings per share during the time were -19.06%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is 66.59%. This publicly-traded company’s shares outstanding now amount to $46.71 million, simultaneously with a float of $40.59 million. The organization now has a market capitalization of $60.73 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is positioning itself at the intersection of immunology and cardiology by targeting inflammation as a fundamental driver of heart disease. This scientific approach reflects a broader shift in the field, where understanding of immune-mediated damage is reshaping how cardiovascular conditions are treated.

Market Momentum

As of April 22, 2026, CRDL closed at $1.51, plunging 7.36%, with trading volume (1.16M shares) significantly above its average of 654,693 shares—highlighting increased market activity during the decline. With a market cap of $168.637M, the stock remains within its 52-week range ($0.8800–$1.71). A 1-year target estimate of $7.45 continues to indicate substantial upside potential as clinical milestones approach.

Mechanism of Action

Cardiol’s therapies, including CardiolRx™, work by modulating the inflammasome pathway, reducing the release of pro-inflammatory cytokines such as IL-1 and IL-6. These cytokines are central to the development of inflammation and fibrosis in cardiovascular disease, making them key therapeutic targets.

Therapeutic Differentiation

Unlike conventional treatments that rely on broad immunosuppression, Cardiol’s targeted approach is designed to preserve immune function while addressing inflammation. This may result in improved safety and tolerability, particularly for chronic conditions requiring long-term management.

Outlook

As the role of inflammation in heart disease becomes increasingly validated, Cardiol’s mechanism-driven strategy positions it well to capitalize on this shift, with potential to deliver differentiated clinical and commercial outcomes.

SOPHiA Genetics SA (SOPH)

Witnessing the stock’s movement on the chart, on April 22, 2026, SOPHiA Genetics SA (NASDAQ: SOPH) set off with pace as it heaved 0.20% to $5.13. During the day, the stock rose to $5.25 and sank to $5.04. Taking a more long-term approach, SOPH posted a 52-week range of $2.59-$5.70.

The Healthcare sector firm’s twelve-monthly sales growth has been -13.68% for the last half of the decade. Meanwhile, its Annual Earnings per share during the time were -13.68%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is 26.92%. This publicly-traded company’s shares outstanding now amount to $68.49 million, simultaneously with a float of $48.11 million. The organization now has a market capitalization of $367.66 million.

April 23, 2026
3 Stocks Worth Adding to Your Watchlist: Cardiol Therapeutics (CRDL), Apyx Medical (APYX), Oramed Pharmaceuticals (ORMP)

Movements in market activity and shifts in investor confidence can often hint at where attention is heading next. Recently, several healthcare-related stocks have experienced a noticeable uptick in trading volume, reflecting heightened interest among market participants. This pattern points to a gradual shift in focus toward companies that may have previously gone largely unnoticed.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is strengthening its long-term investment profile through a combination of financial discipline, intellectual property protection, and a clearly defined commercialization pathway. As the company advances toward key clinical milestones, these elements are critical in supporting execution and reducing overall development risk.

Market Momentum

As of April 22, 2026, CRDL closed at $1.51, plunging 7.36%, with trading volume (1.16M shares) significantly above its average of 654,693 shares—indicating heightened activity amid the pullback. With a market cap of $168.637M, the stock remains within its 52-week range ($0.8800–$1.71). A 1-year target estimate of $7.45 continues to suggest meaningful upside potential as clinical and strategic catalysts unfold.

Financial & IP Strength

Cardiol has secured funding into 2027, providing sufficient runway to complete its Phase III MAVERIC trial and advance pipeline assets such as CRD-38. In addition, the company’s patent portfolio extends through 2040, reinforcing its competitive positioning and supporting long-term revenue potential if its therapies reach commercialization.

Commercial Strategy

Management has outlined plans to pursue partnerships with larger pharmaceutical companies to support global commercialization. This strategy could accelerate time to market, reduce operational risk, and provide access to established expertise in regulatory, manufacturing, and distribution.

Outlook

With strong financial backing, long-term intellectual property protection, and a partnership-driven approach, Cardiol is well-positioned to transition toward commercialization, contingent on successful clinical outcomes.

Apyx Medical Corp (APYX)

Apyx Medical Corp (NASDAQ: APYX) started the day on April 22, 2026, with a price decrease of -1.79% at $3.83. During the day, the stock rose to $4.11 and sank to $3.82. Taking a more long-term approach, APYX posted a 52-week range of $0.83-$4.50.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 4.74%. Meanwhile, its Annual Earnings per share during the time was 4.74%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is -19.26%. This publicly-traded company’s shares outstanding now amount to $41.79 million, simultaneously with a float of $36.28 million. The organization now has a market capitalization of $160.21 million.

Oramed Pharmaceuticals Inc (ORMP)

As of April 22, 2026, Oramed Pharmaceuticals Inc (NASDAQ: ORMP) got off with the flyer as it spiked 1.30% to $3.9. During the day, the stock rose to $3.94 and sank to $3.86. Taking a long-term approach, ORMP posted a 52-week range of $1.84-$3.96.

This publicly-traded company’s shares outstanding now amount to $39.28 million, simultaneously with a float of $31.16 million. The organization now has a market capitalization of $157.74 million. Its Quick Ratio in the last reported quarter now stands at 6.98. Alongside those numbers, its P/E ratio stands at $2.63, and its Beta score is 1.28.

April 23, 2026
3 Stocks Showing Upward Momentum: Zentek (ZTEK), Prenetics Global (PRE), Cardiol Therapeutics (CRDL)

Fluctuations in volume and sentiment are key signals that investors watch when identifying new opportunities. Lately, a number of healthcare stocks have seen a rise in trading activity, highlighting a surge in engagement from the market. This development implies that attention may be turning toward companies that have not yet been in the spotlight.

Zentek Ltd (ZTEK)

Zentek Ltd (NASDAQ: ZTEK) opened the trading on April 22, 2026, with a bit cautious approach as it glided -4.18% to $0.5. During the day, the stock rose to $0.52 and sank to $0.49. Taking a more long-term approach, ZTEK posted a 52-week range of $0.46-$1.84.

The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 35.94%. Meanwhile, its Annual Earnings per share during the time were -35.94%. This publicly-traded company’s shares outstanding now amount to $107.37 million, simultaneously with a float of $102.98 million. The organization now has a market capitalization of $53.24 million.

Prenetics Global Limited (PRE)

Prenetics Global Limited (NASDAQ: PRE) started the day on April 22, 2026, with a price decrease of -0.11% at $17.96. During the day, the stock rose to $18.64 and sunk to $17.81. Taking a more long-term approach, PRE posted a 52-week range of $4.30-$23.63.

It was noted that the giant of the Healthcare sector posted annual sales growth of 27.19% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 27.19%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.95%. This publicly-traded company’s shares outstanding now amounts to $16.83 million, simultaneously with a float of $12.05 million. The organization now has a market capitalization sitting at $302.24 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is expanding its long-term growth profile through a pipeline strategy that extends beyond its lead asset into larger, high-value cardiovascular markets. By advancing next-generation therapies, the company is positioning itself to capture opportunities in conditions with significant unmet need, particularly heart failure.

Market Momentum

As of April 22, 2026, CRDL closed at $1.51, plunging 7.36%, with trading volume (1.16M shares) significantly above its average of 654,693 shares—indicating elevated activity during the pullback. With a market cap of $168.637M, the stock remains within its 52-week range ($0.8800–$1.71). A 1-year target estimate of $7.45 continues to reflect meaningful upside potential as development programs progress.

Pipeline Expansion: CRD-38

The company is developing CRD-38, a subcutaneous therapy designed for more convenient dosing and broader clinical application, particularly in heart failure. This next-generation asset targets both inflammation and fibrosis, key drivers of disease progression that are not adequately addressed by current therapies.

Market Opportunity

Heart failure represents a multi-billion-dollar global market with millions of patients and limited treatment options targeting inflammatory pathways. By advancing CRD-38, Cardiol is positioning itself to enter a large and underserved segment, significantly expanding its potential addressable market beyond pericarditis and myocarditis.

Outlook

As CRD-38 progresses toward clinical development, it could become a key value driver for the company. Success in this program would enhance Cardiol’s long-term growth trajectory and support its evolution into a more diversified cardiovascular innovator.

April 23, 2026
3 Stocks to Watch for Potential Upside: LENZ Therapeutics (LENZ), Cardiol Therapeutics (CRDL), Bioventus (BVS)

Investor behavior and trading patterns often provide valuable clues about where new opportunities may be forming. Recently, there has been a noticeable increase in volume across several healthcare equities, highlighting stronger market involvement. This shift hints that investors are beginning to explore opportunities in companies that have not yet gained widespread attention.

LENZ Therapeutics Inc (NASDAQ: LENZ)

Witnessing the stock’s movement on the chart, on April 21, 2026, LENZ Therapeutics Inc (NASDAQ: LENZ) had a quiet start as it plunged -2.57% to $9.87. During the day, the stock rose to $10.39 and sunk to $9.82. Taking a more long-term approach, LENZ posted a 52-week range of $8.25-$50.40.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 19.13%. Meanwhile, its Annual Earning per share during the time was 19.13%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -37.05%. This publicly-traded company’s shares outstanding now amounts to $31.34 million, simultaneously with a float of $27.67 million. The organization now has a market capitalization sitting at $309.47 million.

Cardiol Therapeutics Inc. (NASDAQ: CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is strengthening its long-term investment profile through a combination of financial stability, intellectual property protection, and a clear path toward commercialization. As the company advances its clinical programs, these foundational elements are critical in supporting execution and reducing overall development risk.

Market Momentum

As of April 21, 2026, CRDL closed at $1.63, surging 7.95%, with trading volume (2.40M shares) significantly exceeding its average of 638,595 shares—indicating strong market participation and investor confidence. With a market cap of $182.039M, the stock is nearing the upper end of its 52-week range ($0.8800–$1.6950). A 1-year target estimate of $7.46 continues to suggest meaningful upside potential as clinical and strategic catalysts unfold.

Financial & IP Strength

Cardiol has secured funding into 2027, providing sufficient runway to complete its Phase III MAVERIC trial and advance pipeline programs such as CRD-38. Additionally, the company’s patent protection extending through 2040 strengthens its competitive positioning and supports long-term revenue potential if its therapies reach commercialization.

Commercial Strategy

The company is pursuing partnerships with larger pharmaceutical firms to support global commercialization. This strategy could accelerate time to market, reduce operational risk, and leverage established expertise in regulatory, manufacturing, and distribution capabilities.

Outlook

With strong financial backing, long-term intellectual property protection, and a partnership-driven approach, Cardiol is well-positioned to transition toward commercialization, contingent on successful clinical outcomes.

Bioventus Inc (NASDAQ: BVS)

Bioventus Inc (NASDAQ: BVS) opened the trading on April 21, 2026, with a bit cautious approach as it glided -6.23% to $9.64. During the day, the stock rose to $10.46 and sunk to $9.62. Taking a more long-term approach, BVS posted a 52-week range of $5.81-$10.76.

The Healthcare sector firm’s twelve-monthly sales growth has been 33.74% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 33.74%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 9.74%. This publicly-traded company’s shares outstanding now amounts to $67.10 million, simultaneously with a float of $46.25 million. The organization now has a market capitalization sitting at $801.61 million.

April 22, 2026
3 Stocks to Watch for Strong Upside: Cardiol Therapeutics (CRDL), Silence Therapeutics (SLN), Caredx (CDNA)

Early signs of market opportunity are frequently tied to rising trading volumes and changing investor perspectives. In recent trading sessions, a number of healthcare stocks have posted significant increases in activity, suggesting growing enthusiasm among investors. This momentum may point to a renewed interest in underappreciated names within the sector.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is distinguishing itself through a mechanism-driven strategy that targets inflammation as a root cause of cardiovascular disease. By focusing on the inflammasome pathway and its downstream cytokines, the company is aligning with a growing shift in medicine toward therapies that address underlying disease biology rather than just symptoms.

Market Momentum

As of April 21, 2026, CRDL closed at $1.63, surging 7.95%, with trading volume (2.40M shares) significantly exceeding its average of 638,595 shares—demonstrating strong investor interest and momentum. With a market cap of $182.039M, the stock is nearing the upper end of its 52-week range ($0.8800–$1.6950). A 1-year target estimate of $7.46 continues to reflect substantial upside potential supported by clinical progress.

Mechanism of Action

Cardiol’s therapies, including CardiolRx™, modulate inflammasome activation, reducing the release of pro-inflammatory cytokines such as IL-1 and IL-6. These cytokines are key contributors to inflammation and fibrosis in cardiovascular diseases, making them critical targets for therapeutic intervention.

Therapeutic Differentiation

Unlike conventional treatments that rely on broad immunosuppression, Cardiol’s targeted approach aims to preserve immune function while delivering anti-inflammatory effects. This could result in a more favorable safety profile, particularly for chronic use, and position the therapy as a differentiated option in the treatment landscape.

Outlook

As the role of inflammation in heart disease becomes increasingly recognized, Cardiol’s approach positions it well to benefit from this paradigm shift, with potential to deliver meaningful clinical and commercial outcomes.

Silence Therapeutics Plc ADR (SLN)

As of April 21, 2026, Silence Therapeutics Plc ADR (NASDAQ: SLN) started slowly as it slid -2.52% to $7.73. During the day, the stock rose to $8.07 and sunk to $7.63. Taking a more long-term approach, SLN posted a 52-week range of $2.91-$8.14.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -4.20%. Meanwhile, its Annual Earning per share during the time was -4.20%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 15.08%. This publicly-traded company’s shares outstanding now amounts to $47.23 million, simultaneously with a float of $38.75 million. The organization now has a market capitalization sitting at $365.09 million.

Caredx Inc (CDNA)

Caredx Inc (NASDAQ: CDNA) flaunted slowness of -2.63% at $20.73, as the Stock market unbolted on April 21, 2026. During the day, the stock rose to $21.65 and sunk to $20.65. Taking a more long-term approach, CDNA posted a 52-week range of $10.96-$23.24.

In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 0.09%. Meanwhile, its Annual Earning per share during the time was 0.09%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 100.00%. This publicly-traded company’s shares outstanding now amounts to $50.92 million, simultaneously with a float of $45.64 million. The organization now has a market capitalization sitting at $1.06 billion.

April 22, 2026
3 Stocks That Could Make Big Moves: Cardiol Therapeutics (CRDL), Opus Genetics (IRD), Vivani Medical (VANI)

Fluctuations in market activity and shifts in investor outlook frequently act as early indicators of potential opportunities in equities. Recently, several healthcare-related stocks have experienced a noticeable uptick in trading volume, pointing to rising engagement from market participants. This pattern implies that investors may be beginning to focus on a selection of overlooked companies within the sector.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is emerging as a high-momentum cardiovascular biotech as investors increasingly focus on late-stage clinical catalysts in underserved inflammatory heart diseases. With its lead candidate advancing through pivotal development, the company is attracting attention as a potential disruptor in a niche yet high-value therapeutic area.

Market Momentum

As of April 21, 2026, CRDL closed at $1.63, surging 7.95%, with trading volume (2.40M shares) significantly exceeding its average of 638,595 shares—indicating strong institutional and retail participation. With a market cap of $182.039M, the stock is approaching the upper end of its 52-week range ($0.8800–$1.6950). A 1-year target estimate of $7.46 continues to highlight substantial upside potential, driven by upcoming clinical milestones.

Clinical Focus: MAVERIC Trial

The Phase III MAVERIC trial remains the company’s primary value driver, evaluating CardiolRx™ in recurrent pericarditis. This late-stage study builds on encouraging Phase II data and is designed to confirm the drug’s ability to reduce recurrence and inflammation. Positive results could support a New Drug Application and position CardiolRx™ as a leading therapy in this indication.

Regulatory & Competitive Positioning

CardiolRx™ has received FDA Orphan Drug Designation, providing potential market exclusivity and regulatory advantages. Combined with its non-immunosuppressive profile, the therapy could offer a differentiated alternative to current treatments, which often carry safety limitations.

Outlook

With strong price momentum and a pivotal trial underway, Cardiol is nearing a critical inflection point. Successful Phase III outcomes could significantly re-rate the stock and establish the company as a key player in inflammation-focused cardiovascular therapeutics.

Opus Genetics Inc (IRD)

Opus Genetics Inc (NASDAQ: IRD) started the day on April 21, 2026, with a price decrease of -3.61% at $5.34. During the day, the stock rose to $5.59 and sunk to $5.32. Taking a more long-term approach, IRD posted a 52-week range of $0.71-$5.81.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 31.49%. Meanwhile, its Annual Earning per share during the time was 31.49%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 38.59%. This publicly-traded company’s shares outstanding now amounts to $69.89 million, simultaneously with a float of $53.56 million. The organization now has a market capitalization sitting at $379.94 million.

Vivani Medical Inc (VANI)

As of April 21, 2026, Vivani Medical Inc (NASDAQ: VANI) started slowly as it slid -8.61% to $1.38. During the day, the stock rose to $1.52 and sunk to $1.35. Taking a more long-term approach, VANI posted a 52-week range of $0.92-$1.92.

In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 27.77%. Meanwhile, its Annual Earning per share during the time was 27.77%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 24.42%. This publicly-traded company’s shares outstanding now amounts to $76.43 million, simultaneously with a float of $36.24 million. The organization now has a market capitalization sitting at $116.81 million.

April 22, 2026
3 Stocks Heating Up Right Now: Cardiol Therapeutics (CRDL), PureTech Health (PRTC), Ascentage Pharma Group International (AAPG)

As global markets continue to navigate shifting economic signals, investors are increasingly gravitating toward sectors defined by resilience and forward-looking growth. Technology-driven industries, in particular, are benefiting from rapid digital transformation and evolving consumer behavior, positioning themselves as key areas where long-term value creation is taking shape.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to build its profile as a late-stage cardiovascular biotech focused on addressing diseases where inflammation is a central but under-treated driver. By advancing CardiolRx™ into pivotal development, the company is targeting a segment of the market where safer, long-term therapies are urgently needed.

Market Momentum

As of April 20, 2026, CRDL closed at $1.51, remaining unchanged, with trading volume (831,993 shares) well above its average of 606,137 shares—indicating sustained investor interest despite flat price movement. With a market cap of $168.637M, the stock is trading near the upper end of its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.46 continues to suggest meaningful upside potential, supported by clinical progress.

Clinical Focus: MAVERIC Trial

The Phase III MAVERIC trial represents the company’s most advanced and important value driver. This study is evaluating CardiolRx™ in patients with recurrent pericarditis, building on earlier data that demonstrated reductions in pain and inflammation. The trial is designed to confirm the drug’s ability to prevent recurrence, a key unmet need in this patient population.

Regulatory Positioning

CardiolRx™ has received FDA Orphan Drug Designation for pericarditis, providing benefits such as potential market exclusivity and regulatory support. This designation enhances the commercial attractiveness of the therapy while reducing competitive pressure in a specialized indication.

Outlook

With strong clinical momentum and a pivotal trial underway, Cardiol is approaching a major inflection point. Positive results from MAVERIC could unlock significant value and position the company for regulatory advancement and commercialization.

PureTech Health Plc ADR (PRTC)

PureTech Health Plc ADR (NASDAQ: PRTC) started the day on April 20, 2026, with a price increase of 0.33% at $18.36. During the day, the stock rose to $18.36 and sunk to $18.13. Taking a more long-term approach, PRTC posted a 52-week range of $14.50-$19.92.

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -32.42%. Meanwhile, its Annual Earning per share during the time was -32.42%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -387.86%. This publicly-traded company’s shares outstanding now amounts to $24.03 million. The organization now has a market capitalization sitting at $446.88 million.

Ascentage Pharma Group International ADR (AAPG)

As of April 20, 2026, Ascentage Pharma Group International ADR (NASDAQ: AAPG) started slowly as it slid -3.80% to $26.36. During the day, the stock rose to $26.40 and sunk to $26.35. Taking a more long-term approach, AAPG posted a 52-week range of $18.87-$48.45.

In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -1.32%. Meanwhile, its Annual Earning per share during the time was -1.32%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 45.44%. This publicly-traded company’s shares outstanding now amounts to $52.23 million. The organization now has a market capitalization sitting at $2.45 billion.

April 21, 2026
3 Stocks Trending in the Market Today: ALPS Group (ALPS), Cardiol Therapeutics (CRDL), Champions Oncology (CSBR)

In an environment shaped by fluctuating interest rates and geopolitical uncertainty, capital allocation is becoming more selective and strategic. Industries that combine strong fundamentals with the ability to adapt—such as renewable energy and infrastructure—are drawing heightened attention as investors seek stability alongside scalable growth potential.

ALPS Group Inc (ALPS)

ALPS Group Inc (NASDAQ: ALPS) established initial surge of 0.19% at $1.0, as the Stock market unbolted on April 20, 2026. During the day, the stock rose to $1.00 and sunk to $0.95. Taking a more long-term approach, ALPS posted a 52-week range of $0.56-$15.00.

This publicly-traded company’s shares outstanding now amounts to $166.40 million, simultaneously with a float of $45.01 million. The organization now has a market capitalization sitting at $166.38 million. It’s Quick Ratio in the last reported quarter now stands at 0.04. In the same vein, ALPS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.73.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is strengthening its clinical narrative through growing evidence that its lead therapy may deliver meaningful improvements in inflammatory heart disease. By focusing on myocarditis, the company is targeting a serious condition with limited treatment options and significant long-term risk.

Market Momentum

As of April 20, 2026, CRDL closed at $1.51, remaining unchanged, with trading volume (831,993 shares) well above its average of 606,137 shares—indicating sustained investor engagement. With a market cap of $168.637M, the stock continues to trade near the upper end of its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.46 reflects strong upside potential tied to clinical milestones.

Clinical Evidence: ARCHER Study

The Phase II ARCHER study evaluated CardiolRx™ in patients with acute myocarditis, a condition that can lead to heart failure or sudden cardiac death. The study reported improvements in heart inflammation, supporting the therapy’s mechanism and reinforcing its potential role in treating this high-risk condition.

Clinical Significance

These findings are particularly important given the lack of targeted therapies for myocarditis. By addressing inflammation without suppressing the immune system, CardiolRx™ may offer a safer and more sustainable treatment approach, potentially improving outcomes and reducing long-term complications.

Outlook

If future studies confirm these results, Cardiol could expand its clinical reach beyond pericarditis into broader cardiovascular indications, strengthening its long-term growth profile and positioning it as a key innovator in inflammation-focused therapies.

Champions Oncology Inc (CSBR)

Witnessing the stock’s movement on the chart, on April 20, 2026, Champions Oncology Inc (NASDAQ: CSBR) set off with pace as it heaved 0.66% to $6.07. During the day, the stock rose to $6.08 and sunk to $5.95. Taking a more long-term approach, CSBR posted a 52-week range of $5.50-$9.63.

This publicly-traded company’s shares outstanding now amounts to $13.89 million, simultaneously with a float of $6.07 million. The organization now has a market capitalization sitting at $84.36 million. It’s Quick Ratio in the last reported quarter now stands at 0.98. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.46. Similarly, its price to free cash flow for trailing twelve months is now 22.08.

April 21, 2026
3 Stocks Investors Should Track Now: Fonar (FONR), Sera Prognostics (SERA), Cardiol Therapeutics (CRDL)

Amid ongoing volatility in traditional markets, focus is steadily moving toward sectors that demonstrate both innovation and durability. Companies leveraging data, automation, and artificial intelligence are emerging as frontrunners, offering new pathways for efficiency and competitive advantage in an increasingly digital economy.

Fonar Corp (FONR)

Fonar Corp (NASDAQ: FONR) opened the trading on April 20, 2026, remained unchanged at $18.8. During the day, the stock rose to $18.83 and sunk to $18.78. Taking a more long-term approach, FONR posted a 52-week range of $12.00-$18.86.

The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 0.90%. Meanwhile, its Annual Earning per share during the time was 0.90%. This publicly-traded company’s shares outstanding now amounts to $6.17 million, simultaneously with a float of $5.43 million. The organization now has a market capitalization sitting at $118.05 million.

Sera Prognostics Inc (SERA)

Sera Prognostics Inc (NASDAQ: SERA) started the day on April 20, 2026, with a price decrease of -0.43% at $2.29. During the day, the stock rose to $2.33 and sunk to $2.22. Taking a more long-term approach, SERA posted a 52-week range of $1.37-$4.09.

It was noted that the giant of the Healthcare sector posted annual sales growth of -0.71% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -0.71%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -0.50%. This publicly-traded company’s shares outstanding now amounts to $37.98 million, simultaneously with a float of $27.09 million. The organization now has a market capitalization sitting at $89.64 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is advancing a broader pipeline strategy designed to extend its reach beyond niche indications into large-scale cardiovascular markets. By developing next-generation therapies, the company is positioning itself to capture opportunities in conditions like heart failure, where unmet need remains substantial.

Market Momentum

As of April 20, 2026, CRDL closed at $1.51, remaining unchanged, with trading volume (831,993 shares) well above its average of 606,137 shares—indicating sustained investor interest. With a market cap of $168.637M, the stock continues to trade near the upper end of its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.46 continues to suggest meaningful upside potential as development programs advance.

Pipeline Expansion: CRD-38

The company is developing CRD-38, a subcutaneous therapy designed for more convenient dosing and broader application, particularly in heart failure. This therapy targets both inflammation and fibrosis, two key drivers of disease progression that are not adequately addressed by current treatments.

Market Opportunity

Heart failure represents a multi-billion-dollar global market with millions of patients and limited therapies targeting inflammatory pathways. By advancing CRD-38, Cardiol is positioning itself to enter a large and underserved market, significantly expanding its long-term commercial potential.

Outlook

As CRD-38 progresses toward clinical development, it has the potential to become a major growth driver. Success in this program could transform Cardiol into a more diversified cardiovascular company with broader market exposure.

April 21, 2026